21 results
8-K
EX-99.4
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
of operations and cause reputational damage. Elicio cannot assure that any such issues relating to the manufacture of ELI-002 or any other product candidate … , contractual damages, reputational harm, and diminished profits and future earnings.
Physicians, other health care providers and third-party payors
8-K
EX-99.3
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of Elicio’s operations, any … , negative publicity, reputational harm and a potential loss of business and goodwill.
The GDPR may also impose additional compliance obligations
424B3
ELTX
Elicio Therapeutics Inc.
28 Apr 23
Prospectus supplement
4:07pm
viruses. Any security breach or other incident, whether real or perceived, would cause Angion to lose product sales, if any, and suffer reputational … reputational damage. Elicio cannot assure that any such issues relating to the manufacture of ELI-002 or any other product candidate will not occur
S-4/A
eppf mmyi0sl319
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
10-Q
40ek9
17 May 21
Quarterly report
6:03am
10-K
m0sfwz
30 Mar 21
Annual report
5:00pm
424B4
eah0s 77j140vlm
5 Feb 21
Prospectus supplement with pricing info
5:12pm
DRS/A
xzz 36f55t5
15 Dec 20
Draft registration statement (amended)
12:00am